Please use this identifier to cite or link to this item:
Title: The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study
Austin Authors: Roach, Paul J;Francis, Roslyn ;Emmett, Louise ; Hsiao, Edward; Kneebone, Andrew; Hruby, George;Eade, Thomas ;Nguyen, Quoc A ;Thompson , Benjamin D ;Cusick , Thomas ;McCarthy, Michael ;Tang, Colin ;Ho, Bao ;Stricker, Philip D ;Scott , Andrew M 
Affiliation: Royal North Shore Hospital, Sydney, New South Wales, Australia
Australasian Radiopharmaceutical Trials Network, Sydney, New South Wales, Australia
University of Sydney, Sydney, NSW, Australia
 University of Western Australia, Perth, Western Australia, Australia
 Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
St Vincent's Hospital, Sydney, New South Wales, Australia
University of New South Wales, Sydney, New South Wales, Australia
The Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Australian Prostate Cancer Research Centre – New South Wales (APCRC‐NSW), Sydney, New South Wales, Australia
Fiona Stanley Hospital, Perth, Western Australia, Australia
St Vincent's Prostate Cancer Centre, Sydney, New South Wales, Australia
Austin Health, Heidelberg, Victoria, Australia
Olivia Newton‐John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia
University of Melbourne, Melbourne, Victoria, Australia
Issue Date: Jan-2018 2017-06-23
Publication information: Journal of Nuclear Medicine 2018; 59(1): 82-88
Abstract: 68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging impacts on management intent in patients with primary or recurrent prostate cancer. Methods: Prior to undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate follow up questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether their management plan would change. Results: A total of 431 patients with prostate cancer from four Australian centers had pre- and post-68Ga-PSMA management plans completed. Scans were performed for primary staging of intermediate and high risk disease in 25% patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure post definitive surgery and /or radiation treatment (62% change in management intent) compared with patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39% and distant metastatic disease in 16% of patients. Conclusion:68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. This demonstrates the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.
DOI: 10.2967/jnumed.117.197160
ORCID: 0000-0002-6656-295X
PubMed URL:
Type: Journal Article
Subjects: Oncology
Management impact
Prostate cancer
Type of Clinical Study or Trial: Multicentre Studies
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.